药物警戒中致医务人员的函的欧美对比研究与启示

doi:10.19803/j.1672-8629.2022.03.09

中国药物警戒 ›› 2022, Vol. 19 ›› Issue (3): 275-278.
DOI: 10.19803/j.1672-8629.2022.03.09

药物警戒中致医务人员的函的欧美对比研究与启示

梁佳琪¹, 邵蓉¹, 柳鹏程¹, 李明², 任经天³, 汤韧³, 王越^4,*

¹中国药科大学药品监管科学研究院,江苏南京 211198;
²江苏省药品不良反应监测中心,江苏南京 210002;
³国家药品监督管理局药品评价中心/国家药品监督管理局药物警戒研究与评价重点实验室,北京 100022;
⁴江苏省市场监督管理局,江苏南京 210036

收稿日期:2021-05-27 出版日期:2022-03-15 发布日期:2022-03-16
通讯作者: ^*王越,男,博士,主任药师,药品监管。E-mail：wangy@jsfda.gov.cn
作者简介:梁佳琪,女,在读硕士,监管科学。
基金资助:
2021年中国药科大学大学生创新创业训练计划项目（202110316134）; 国家药品监督管理局药品评价中心课题（CDRW20204007）

Characteristics of dear health care provider letters in Europe and America

LIANG Jiaqi¹, SHAO Rong¹, LIU Pengcheng¹, LI Ming², RENG Jingtian³, TANG Ren³, WANG Yue^4,*

¹Institute of Regulatory Science for Medical Products, China Pharmaceutical University, Nanjing Jiangsu 211198, China;
²Jiangsu Center for ADR Monitoring, Nanjing Jiangsu 210002, China;
³Center for Drug Reevaluation, NMPA/ NMPA Key Laboratory for Research and Evaluation of Pharmacovigilance, Beijing 100022, China;
⁴Jiangsu Provincial Administration for Market Regulation, Jiangsu Nanjing 210036, China

Received:2021-05-27 Online:2022-03-15 Published:2022-03-16

摘要/Abstract

摘要： 目的为我国进行“致医务人员的函”风险沟通方式提供思路。方法通过查阅欧美国家药品监督管理部门“致医务人员的函”实施的相关指南及法规,比较研究其药物警戒中“致医务人员的函”的发起、实施流程等方面的不同。结果欧美国家在“致医务人员的函”工作中,分类、发起情况、目标受众的选择及有效性评估等方面有所不同,可以为我国开展此项工作提供参考。结论建议我国尽快开展“致医务人员的函”工作,出台相关指南,并详细规定“致医务人员的函”实施流程及有效性评估等细节。

关键词: 欧盟, 美国, 致医务人员的函, 风险沟通, 药物警戒

Abstract: Objective To give advice on risk communication methods related to Dear Health Care Provider Letters in China. Methods The difference in the initiation, implementation process, and effectiveness evaluation of Dear Health Care Provider Letters was analyzed by reviewing the related guidelines and regulations for the implementation of Dear Health Care Provider Letters in Europe and the United States. Results There was difference in specific classification, initiation, and details of Dear Health Care Provider Letters in Europe and the United States, which could serve as reference for China. Conclusion It is recommended that China start Dear Health Care Provider Letters, issue relevant guidelines and specify the details.

Key words: the European Union, the United States, Dear Health Care Provider Letter, risk communication, pharmacovigilance

中图分类号:

R951

梁佳琪, 邵蓉, 柳鹏程, 李明, 任经天, 汤韧, 王越. 药物警戒中致医务人员的函的欧美对比研究与启示[J]. 中国药物警戒, 2022, 19(3): 275-278.

LIANG Jiaqi, SHAO Rong, LIU Pengcheng, LI Ming, RENG Jingtian, TANG Ren, WANG Yue. Characteristics of dear health care provider letters in Europe and America[J]. Chinese Journal of Pharmacovigilance, 2022, 19(3): 275-278.

参考文献

[1] NMPA. NMPA announcement on issuing good pharmacovigilance practices (No.65 of2021)[EB/OL].(2021-05-13)[2021-07-23]. https://www.nmpa.gov.cn/xxgk/ggtg/qtggtg/20210513151827179.html.
[2] MATHIAS M, SUSANNE K, LOUISE DBM, et al.The effectiveness of direct to healthcare professional communication - a systematic review of communication factor studies[J]. Res Social Adm Pharm, 2019, 15(5): 475-482.
[3] PIENING S, HAAIJER-RUSKAMP FM, GRAEFF DPA, et al.Healthcare professionals' self-reported experiences and preferences related to direct healthcare professional communications: a survey conducted in the Netherlands[J]. Drug Saf, 2012, 35(11): 1061-1072.
[4] LU KR, HU M, JIANG XH.Consideration on risk communication method in the drug risk management[J]. China Pharmacy(中国药房), 2010, 21(17): 1545-1549.
[5] CHENG H, LI XX.Post-marketing drug risk communication and exchange[J]. Clinical Medication Journal(临床药物治疗杂志), 2011, 9(3): 55-58.
[6] LI S, YANG Y.Drug risk communication method of America and Canada and its implication in China[J]. Chinese Journal of New Drugs(中国新药杂志), 2012, 21(18): 2104-2108.
[7] ZHU H, LIU LR, LAN GZ, et al.Comparison of the application of drug risk communication between America and China based on the case of rosiglitazone[J]. Chinese Journal of New Drugs(中国新药杂志), 2016, 25(10): 1089-1094.
[8] WU SF, JIN Y, CHANG H, et al.Drug risk communication in the European Union and United States between regulators and the public[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2020, 17(2): 87-92.
[9] ZHANG D, LYU JT, SONG HB, et al. Study on drug risk commun-ication among drug regulatory agencies in the European Union, United States and Asian countries[J/OL]. Chinese Journal of Pharmacovigilance(中国药物警戒),(2021-02-02)[2021-04-05]. http://kns.cnki.net/kcms/detail/11.5219.R.20210202.1136.038.html.
[10] XIAO HL.Introduction to DHCP letter format and content guidance recently issued by FDA[J]. Drug Evaluation Research(药物评价研究), 2017, 40(6): 725-730.
[11] WEI FQ, ZHANG W, YANG Y.Implementation of US FDA's drug risk evaluation and mitigation strategies[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2020, 17(12): 871-876.
[12] Govinfo. Congress of the United States. 21 USC 355-1[EB/OL].(2018)[2021-04-11]. https://www.govinfo.gov/app/collection/uscode/2018/.
[13] FDA. Administrative Committee of the Federal Register.21 CFR 200.5[EB/OL].(2016-04-01)[2021-04-11]. http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=200&showFR=1&subpartNode=21:4.0.1.1.1.1.
[14] FDA. Guidance for industry and fda staff dear health care provider letters: improving communication of important Safety Information [EB/OL]. (2017-02-08)[2017-03-23]. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/dear-health-care-provider-letters-improving-communication-important-safety-information.
[15] FDA. Guidance for industry development and use of risk minimization action plans, risk MAP [EB/OL]. (2005-03) [2021-04-11]. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/development-and-use-risk-minimization-action-plans.
[16] European Medicines Agency. Guideline on good pharmacovigilance practices(GVP):module XV:Safety communication:rev.1[EB/OL].(2017-03-28)[2021-04-11]. https://www.ema.europa.eu/en/human-regulatory/post-authorisation/pharmacovigilance/good-pharmacovigilance-practices.
[17] Health Products Regulatory Authority. COVID-19 mRNA Vaccines comirnaty and spikevax: risk of myocarditis and pericarditis[EB/OL].(2021-07-19)[2020-08-18]. important-safety-information-covid-19-mrna-vaccines-comirnaty-and-spikevax00f10f2697826eee9b55ff00008c97d0.pdf (hpra.ie).
[18] European Medicines Agency. Guideline on good pharmacovigilance practices(GVP):module XVI:Risk minimisation measures: selection of tools and effectiveness indicators:rev.2[EB/OL].(2017-10-09)[2021-04-11]. https://www.ema.europa.eu/en/human-regulatory/post-authorisation/pharmacovigilance/good-pharmacovigilance-practices.

药物警戒中致医务人员的函的欧美对比研究与启示

Characteristics of dear health care provider letters in Europe and America

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	刘敏, 陈艳, 刘文东, 王海学. 药物临床试验期间安全性数据快速报告的更新与思考[J]. 中国药物警戒, 2024, 21(1): 98-101.
[2]	夏旭东, 黎美霞, 孙阳, 杨胜亚. 药品上市许可持有人药物警戒远程检查流程探讨[J]. 中国药物警戒, 2023, 20(9): 967-970.
[3]	里筱竹, 王蔷, 逄瑜, 张轶菁. 个例药品不良反应报告管理浅析与思考[J]. 中国药物警戒, 2023, 20(9): 975-977.
[4]	逄瑜, 刘博, 吕少俐, 王涛, 邢颖, 秦星宇, 田月洁, 吴文宇. 基于国际药物警戒经验探讨收集患者报告的意义[J]. 中国药物警戒, 2023, 20(9): 978-981.
[5]	沈艳杰, 吴奕卿. 临床试验期间不良事件管理的实践与思考[J]. 中国药物警戒, 2023, 20(9): 982-986.
[6]	刘文东, 崔欢欢, 王晓晗, 苏娴, 王海学. 我国儿童用药临床试验期间药物警戒监管体系现状及思考[J]. 中国药物警戒, 2023, 20(9): 1002-1006.
[7]	黄锦坚, 张晓朦, 张冰, 丁雪丽, 杨莹, 林志健. 降尿酸药物的心血管风险信号挖掘及机制研究[J]. 中国药物警戒, 2023, 20(8): 866-871.
[8]	张雨琪, 徐昕怡, 朱兰, 朱彦. 药品剂型标准术语的比较研究[J]. 中国药物警戒, 2023, 20(8): 904-910.
[9]	何雄, 马俊龙, 阳国平. 基于FAERS对靶向HER2抗体偶联药品不良反应/事件的分析[J]. 中国药物警戒, 2023, 20(8): 915-920.
[10]	郑轶, 罗枭, 张朋朋, 刘永梅, 叶小飞, 郭晓晶, 陈霞, 贺佳. 基于主动监测系统的免疫检查点抑制剂心肌炎不良反应探索[J]. 中国药物警戒, 2023, 20(6): 634-638.
[11]	陈枭, 郭晓晶, 许金芳, 韦连慧, 陈晨鑫, 梁际洲, 郑轶, 叶小飞. 机器学习方法在FAERS布加替尼不良反应信号检测中的应用[J]. 中国药物警戒, 2023, 20(6): 639-645.
[12]	赵稳华, 舒鹤, 倪晨明, 郭晋敏. 基于FAERS数据库的氨吡啶缓释片不良反应信号挖掘分析[J]. 中国药物警戒, 2023, 20(6): 684-690.
[13]	梁士兵, 余泽宇, 孔令垚, 晏利姣, 韩梅, 吴嘉瑞, 刘兆兰, 刘建平. 文献计量法在中药药物警戒领域中的应用价值及展望[J]. 中国药物警戒, 2023, 20(5): 591-594.
[14]	霍佩琼, 郑鹏, 苏振浩. 特殊或重大疾病零售药店开展药物警戒活动的思考[J]. 中国药物警戒, 2023, 20(4): 428-432.
[15]	裴宇盛, 陈晨, 蔡彤, 赵小燕, 高华. 中国与美国药典细菌内毒素检查法应用指导原则的比较和解读[J]. 中国药物警戒, 2023, 20(3): 317-320.